Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma

被引:49
|
作者
Krieger, D. A. [1 ]
Hudgins, P. A. [2 ]
Nayak, G. K. [7 ]
Baugnon, K. L. [2 ]
Corey, A. S. [2 ]
Patel, M. R. [3 ]
Beitler, J. J. [3 ,4 ,5 ]
Saba, N. F. [5 ]
Liu, Y. [6 ]
Aiken, A. H. [2 ]
机构
[1] Hackensack Univ Med Ctr, Dept Radiol, Hackensack, NJ USA
[2] Emory Univ, Sch Med, Dept Radiol & Imaging Sci, Atlanta, GA USA
[3] Emory Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Atlanta, GA USA
[4] Emory Univ, Sch Med, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA USA
[5] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
[6] Emory Univ, Sch Med, Dept Biostat, Winship Canc Inst, Atlanta, GA USA
[7] NYU, Dept Radiol, Sch Med, 560 1st Ave, New York, NY 10016 USA
关键词
SURVEILLANCE PET/CT; CANCER; UTILITY;
D O I
10.3174/ajnr.A5157
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND AND PURPOSE: The Head and Neck Imaging Reporting and Data System (NI-RADS) surveillance template for head and neck cancer includes a numeric assessment of suspicion for recurrence (1-4) for the primary site and neck. Category 1 indicates no evidence of recurrence; category 2, low suspicion of recurrence; category 3, high suspicion of recurrence; and category 4, known recurrence. Our purpose was to evaluate the performance of the NI-RADS scoring system to predict local and regional disease recurrence or persistence. MATERIALS AND METHODS: This study was classified as a quality-improvement project by the institutional review board. A retrospective database search yielded 500 consecutive cases interpreted using the NI-RADS template. Cases without a numeric score, non-squamous cell carcinoma primary tumors, and primary squamous cell carcinoma outside the head and neck were excluded. The electronic medical record was reviewed to determine the subsequent management, pathology results, and outcome of clinical and radiologic follow-up. RESULTS: A total of 318 scans and 618 targets (314 primary targets and 304 nodal targets) met the inclusion criteria. Among the 618 targets, 85.4% were scored NI-RADS 1; 9.4% were scored NI-RADS 2; and 5.2% were scored NI-RADS 3. The rates of positive disease were 3.79%, 17.2%, and 59.4% for each NI-RADS category, respectively. Univariate association analysis demonstrated a strong association between the NI-RADS score and ultimate disease recurrence, with P < .001 for primary and regional sites. CONCLUSIONS: The baseline performance of NI-RADS was good, demonstrating significant discrimination among the categories 1-3 for predicting disease.
引用
收藏
页码:1193 / 1199
页数:7
相关论文
共 50 条
  • [31] Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck
    Hanna, Glenn J.
    Liu, Hongye
    Jones, Robert E.
    Bacay, Alyssa F.
    Lizotte, Patrick H.
    Ivanova, Elena V.
    Bittinger, Mark A.
    Cavanaugh, Megan E.
    Rode, Amanda J.
    Schoenfeld, Jonathan D.
    Chau, Nicole G.
    Haddad, Robert I.
    Lorch, Jochen H.
    Wong, Kwok-Kin
    Uppaluri, Ravindra
    Hammerman, Peter S.
    ORAL ONCOLOGY, 2017, 67 : 61 - 69
  • [32] Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma
    Zargar, Mahdi
    McFarlane, Thomas
    Chan, Kelvin K. W.
    Wong, William W. L.
    ONCOLOGIST, 2018, 23 (02) : 225 - 233
  • [33] Platinum rechallenge in recurrent head and neck squamous cell carcinoma after primary chemoradiation
    Rambeau, A.
    Licaj, I
    Gery, B.
    Gervais, R.
    Florescu, C.
    Babin, E.
    De Raucourt, D.
    Johnson, A.
    Thariat, J.
    EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES, 2019, 136 (04) : 257 - 261
  • [34] Residual neck disease management in squamous-cell carcinoma of the head and neck treated with radiotherapy plus cetuximab
    Montal, R.
    Oliva, M.
    Taberna, M.
    De Avila, L.
    Rovira, A.
    Cos, M.
    Manos, M.
    Navarro, V.
    Nogues, J.
    Lozano, A.
    Rodriguez, L.
    Vilajosana, E.
    Vazquez, S.
    Mesia, R.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (11) : 1140 - 1146
  • [35] Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
    Okada, Takuro
    Matsuki, Takashi
    Fushimi, Chihiro
    Okamoto, Isaku
    Sato, Hiroki
    Kondo, Takahito
    Tokashiki, Kunihiko
    Ito, Tatsuya
    Masubuchi, Tatsuo
    Tada, Yuichiro
    Miura, Kouki
    Hanyu, Kenji
    Omura, Go
    Takahashi, Hideki
    Yamashita, Taku
    Oridate, Nobuhiko
    Tsukahara, Kiyoaki
    ANTICANCER RESEARCH, 2022, 42 (10) : 4907 - 4912
  • [36] Allergy History and Immunotherapy Response in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Alkhatib, Hosam H.
    Maroun, Christopher A.
    Guller, Meytal
    Cooper, Dylan J.
    Wu, Evan S.
    Eisele, David W.
    Fakhry, Carole
    Pardoll, Drew
    Seiwert, Tanguy Y.
    Zhu, Gangcai
    Mandal, Rajarsi
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2024, 170 (03) : 828 - 836
  • [37] A six-mRNA prognostic model to predict survival in head and neck squamous cell carcinoma
    Tian, Saisai
    Menge, Guofeng
    Zhang, Weidong
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 131 - 142
  • [38] Developing and validating a nomogram to predict suicide risk of patients with head and neck squamous cell carcinoma
    Deng, Junyue
    Ai, Ping
    PSYCHOGERIATRICS, 2024, 24 (03) : 734 - 736
  • [39] Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck
    El Rassy, Elie
    Assi, Tarek
    Bakouny, Ziad
    El Karak, Fadi
    Pavlidis, Nicholas
    Ghosn, Marwan
    FUTURE ONCOLOGY, 2019, 15 (08) : 909 - 924
  • [40] Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
    Hanna, Glenn J.
    O'Neill, Anne
    Shin, Kee-Young
    Wong, Kristine
    Jo, Vickie Y.
    Quinn, Charles T.
    Cutler, Jennifer M.
    Flynn, Michelle
    Lizotte, Patrick H.
    Annino, Donald J., Jr.
    Goguen, Laura A.
    Kass, Jason, I
    Rettig, Eleni M.
    Sethi, Rosh K., V
    Lorch, Jochen H.
    Schoenfeld, Jonathan D.
    Margalit, Danielle N.
    Tishler, Roy B.
    Everett, Peter C.
    Desai, Anupam M.
    Cavanaugh, Megan E.
    Paweletz, Cloud P.
    Egloff, Ann Marie
    Uppaluri, Ravindra
    Haddad, Robert, I
    CLINICAL CANCER RESEARCH, 2022, 28 (03) : 468 - 478